284 related articles for article (PubMed ID: 27563673)
1. Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options.
Rodrigues D; Longatto-Filho A; Martins SF
Biomed Res Int; 2016; 2016():6896024. PubMed ID: 27563673
[TBL] [Abstract][Full Text] [Related]
2. Cancer Stem Cells and Molecular Biology Test in Colorectal Cancer: Therapeutic Implications.
Effendi-Ys R
Acta Med Indones; 2017 Oct; 49(4):351-359. PubMed ID: 29348387
[TBL] [Abstract][Full Text] [Related]
3. MicroRNAs as Regulators, Biomarkers and Therapeutic Targets in the Drug Resistance of Colorectal Cancer.
Xie T; Huang M; Wang Y; Wang L; Chen C; Chu X
Cell Physiol Biochem; 2016; 40(1-2):62-76. PubMed ID: 27842308
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment selection of regimen according to genetic analysis improves the efficacy of chemotherapy in the first line treatment of metastatic colorectal cancer.
Kim DY; Paek TY; Oh SY; Kim YB; Lee JH; Lee MY; Choi ZS; Suh KW
J Surg Oncol; 2014 Mar; 109(3):250-4. PubMed ID: 24318863
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
De Mattia E; Cecchin E; Toffoli G
Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
[TBL] [Abstract][Full Text] [Related]
6. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
7. Recent applications of chemosensitivity tests for colorectal cancer treatment.
Yoon YS; Kim JC
World J Gastroenterol; 2014 Nov; 20(44):16398-408. PubMed ID: 25469008
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer.
Grapsa D; Syrigos K; Saif MW
Expert Rev Anticancer Ther; 2015; 15(11):1267-81. PubMed ID: 26506906
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab in the treatment of patients with colorectal cancer.
Garrett CR; Eng C
Expert Opin Biol Ther; 2011 Jul; 11(7):937-49. PubMed ID: 21557708
[TBL] [Abstract][Full Text] [Related]
10. Genetic markers of recurrence in colorectal cancer.
Smolle MA; Pichler M; Haybaeck J; Gerger A
Pharmacogenomics; 2015; 16(11):1315-28. PubMed ID: 26266878
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive response factors in colorectal cancer patients: between hope and reality.
De Divitiis C; Nasti G; Montano M; Fisichella R; Iaffaioli RV; Berretta M
World J Gastroenterol; 2014 Nov; 20(41):15049-59. PubMed ID: 25386053
[TBL] [Abstract][Full Text] [Related]
12. Alternative spliced variants as biomarkers of colorectal cancer.
Yi Q; Tang L
Curr Drug Metab; 2011 Dec; 12(10):966-74. PubMed ID: 21787266
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer.
Baek SK; Lee KT; Bae SB; Lee SC
Korean J Intern Med; 2019 Nov; 34(6):1188-1196. PubMed ID: 31346151
[TBL] [Abstract][Full Text] [Related]
14. Options for Second-Line Treatment in Metastatic Colorectal Cancer.
Lee JJ; Sun W
Clin Adv Hematol Oncol; 2016 Jan; 14(1):46-54. PubMed ID: 27057668
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
16. A small cog in a big wheel: PIK3CA mutations in colorectal cancer.
Stintzing S; Lenz HJ
J Natl Cancer Inst; 2013 Dec; 105(23):1775-6. PubMed ID: 24231451
[No Abstract] [Full Text] [Related]
17. Predictive markers for colorectal cancer: current status and future prospects.
Longley DB; McDermott U; Johnston PG
Clin Colorectal Cancer; 2003 Feb; 2(4):223-30. PubMed ID: 12620141
[TBL] [Abstract][Full Text] [Related]
18. Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance.
Zhai Z; Yu X; Yang B; Zhang Y; Zhang L; Li X; Sun H
Semin Cell Dev Biol; 2017 Apr; 64():107-115. PubMed ID: 27578007
[TBL] [Abstract][Full Text] [Related]
19. Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases.
Bendardaf R; Lamlum H; Ristamäki R; Korkeila E; Syrjänen K; Pyrhönen S
Acta Oncol; 2008; 47(6):1046-53. PubMed ID: 17943475
[TBL] [Abstract][Full Text] [Related]
20. Current and evolving biomarkers for precision oncology in the management of metastatic colorectal cancer.
Henry JT; Johnson B
Chin Clin Oncol; 2019 Oct; 8(5):49. PubMed ID: 31500426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
